Submitted by ja607 on
Title | Emerging Targets for Cardiovascular Disease Prevention in Diabetes. |
Publication Type | Journal Article |
Year of Publication | 2020 |
Authors | Stitziel, NO, Kanter, JE, Bornfeldt, KE |
Journal | Trends Mol Med |
Volume | 26 |
Issue | 8 |
Pagination | 744-757 |
Date Published | 2020 08 |
ISSN | 1471-499X |
Abstract | Type 1 and type 2 diabetes mellitus (T1DM and T2DM) increase the risk of atherosclerotic cardiovascular disease (CVD), resulting in acute cardiovascular events, such as heart attack and stroke. Recent clinical trials point toward new treatment and prevention strategies for cardiovascular complications of T2DM. New antidiabetic agents show unexpected cardioprotective benefits. Moreover, genetic and reverse translational strategies have revealed potential novel targets for CVD prevention in diabetes, including inhibition of apolipoprotein C3 (APOC3). Modeling and pharmacology-based approaches to improve insulin action provide additional potential strategies to combat CVD. The development of new strategies for improved diabetes and lipid control fuels hope for future prevention of CVD associated with diabetes. |
DOI | 10.1016/j.molmed.2020.03.011 |
Alternate Journal | Trends Mol Med |
PubMed ID | 32423639 |
PubMed Central ID | PMC7395866 |
Grant List | R35 HL150754 / HL / NHLBI NIH HHS / United States U24 DK076169 / DK / NIDDK NIH HHS / United States U24 DK115255 / DK / NIDDK NIH HHS / United States R01 HL126028 / HL / NHLBI NIH HHS / United States DP3 DK108209 / DK / NIDDK NIH HHS / United States R01 HL131961 / HL / NHLBI NIH HHS / United States R21 AI135447 / AI / NIAID NIH HHS / United States P01 HL092969 / HL / NHLBI NIH HHS / United States P30 DK017047 / DK / NIDDK NIH HHS / United States R01 HL127694 / HL / NHLBI NIH HHS / United States UM1 HG008853 / HG / NHGRI NIH HHS / United States |